TG Therapeutics reported 571K in Gross Profit on Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Gross Profit On Sales Change
TG Therapeutics TGTX:US 571K 1.21M
Amgen AMGN:US $ 5084M 407M
Ardelyx ARDX:US $ 2.39M 2M
Bayer BAYN:GR 7.14B 2.32B
Biogen BIIB:US $ 2105.1M 327.2M
Corcept Therapeutics CORT:US $ 102.07M 9.63M
Curis CRIS:US $ 2.35M 0.38M
Dynavax Technologies DVAX:US $ 173.1M 99.06M
Gilead Sciences GILD:US $ 4818M 348M
Infinity Pharmaceuticals INFI:US $ 0.27M 0.01M
Intercept Pharmaceuticals ICPT:US $ 71.45M 16.38M
Johnson & Johnson JNJ:US $ 16101M 273M
Karyopharm Therapeutics KPTI:US $ 38.74M 7.5M
Novartis NOVN:VX 9.34B 277M
Ptc Therapeutics PTCT:US $ 155.89M 17.29M
Puma Biotechnology PBYI:US $ 44.6M 9.71M
Regeneron Pharmaceuticals REGN:US $ 2560.1M 0.1M
Vertex Pharmaceuticals VRTX:US $ 1934.4M 82.7M